Shanghai Haohai repurchases H shares, maintains issued capital

Shanghai Haohai Biological Technology Co., Ltd. announced repurchases of its H shares on November 27, 2025. A total of 78,900 H shares were repurchased on the Exchange at prices ranging from HK$27.64 to HK$27.98 per share, with an aggregate price paid of HK$2,199,366. These repurchases did not result in a change to the total number of issued H shares, which remained at 38,529,240. The company’s A shares also remained constant at 190,203,760, bringing the total issued shares to 194,051,855.

The repurchases are part of a mandate granted on June 10, 2025, authorizing the company to repurchase up to 3,914,184 shares. As of November 27, 2025, 1,637,200 shares have been repurchased under this mandate, representing 4.1827% of the issued shares (excluding treasury shares) at the time of the resolution. The repurchased shares are currently held and not cancelled, leading to no change in the closing balance of issued shares.

The company's total number of issued ordinary shares (excluding treasury shares) stands at 228,733,000, comprising 190,203,760 A shares and 38,529,240 H shares. The moratorium period for any issue of new shares or sale of treasury shares after these repurchases extends until December 27, 2025.